Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity

Bibliography

• Hornberg JJ, Mow T. How can we discover safer drugs? Future Med Chem 2014;6:481-3
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007;35:1-8
   PubMed Web of Science ®Google Scholar
• McGill MR, Staggs VS, Sharpe MR, et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology 2014;60:1336-45
   PubMed Web of Science ®Google Scholar
• Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7:165-82
   PubMed Web of Science ®Google Scholar
• Greer ML, Barber J, Eakins J, Kenna JG. Cell based approaches for evaluation of drug-induced liver injury. Toxicology 2010;268:125-31
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32:504-13
   PubMed Web of Science ®Google Scholar
• Khetani SR, Berger DR, Ballinger KR, et al. Microengineered liver tissues for drug testing. J Lab Autom 2015. [Epub ahead of print]
   Google Scholar
• Monks TJ, Lau SS. Reactive intermediates and their toxicological significance. Toxicology 1988;52:1-53
   PubMed Web of Science ®Google Scholar
• Leblanc A, Shiao TC, Roy R, Sleno L. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching. Rapid Commun Mass Spectrom 2010;24:1241-50
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Ma X. Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol 2011;24:744-51
   PubMed Web of Science ®Google Scholar
• Li AP. In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development. Curr Top Med Chem 2014;14:1325-38
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-90
   PubMedGoogle Scholar
• Guengerich FP, Gillam EM, Shimada T. New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 1996;26:551-83
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17
   PubMed Web of Science ®Google Scholar
• McKinnon RA, Burgess WM, Hall PM, et al. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36:259-67
   PubMed Web of Science ®Google Scholar
• Granvil CP, Yu AM, Elizondo G, et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 2003;31:548-58
   PubMed Web of Science ®Google Scholar
• Cheng J, Ma X, Gonzalez FJ. Pregnane X receptor- and CYP3A4-humanized mouse models and their applications. Br J Pharmacol 2011;163:461-8
   PubMed Web of Science ®Google Scholar
• Kroetz DL, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther 2010;87:109-16
   PubMed Web of Science ®Google Scholar
• Yan Q. Membrane transporters and drug development: relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology. Methods Mol Biol 2010;637:1-21
   PubMedGoogle Scholar
• Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39
   PubMed Web of Science ®Google Scholar
• Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008;327:288-99
   PubMed Web of Science ®Google Scholar
• Scheer N, Snaith M, Wolf CR, Seibler J. Generation and utility of genetically humanized mouse models. Drug Discov Today 2013;18:1200-11
   PubMed Web of Science ®Google Scholar
• Scheer N, Wolf CR. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica 2014;44:96-108
   PubMed Web of Science ®Google Scholar
• Shen HW, Jiang XL, Gonzalez FJ, Yu AM. Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metab 2011;12:997-1006
   PubMed Web of Science ®Google Scholar
• Boverhof DR, Chamberlain MP, Elcombe CR, et al. Transgenic animal models in toxicology: historical perspectives and future outlook. Toxicol Sci 2011;121:207-33
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Otto DM, Carrie D, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003;278:13480-6
   PubMed Web of Science ®Google Scholar
• Wu L, Gu J, Weng Y, et al. Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. Genesis 2003;36:177-81
   PubMed Web of Science ®Google Scholar
• Scheer N, McLaughlin LA, Rode A, et al. Deletion of 30 murine cytochrome P450 genes results in viable mice with compromised drug metabolism. Drug Metab Dispos 2014;42:1022-30
   PubMed Web of Science ®Google Scholar
• Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 1998;152:193-9
   PubMed Web of Science ®Google Scholar
• Heidel SM, MacWilliams PS, Baird WM, et al. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene. Cancer Res 2000;60:3454-60
   PubMed Web of Science ®Google Scholar
• Nebert DW, Shi Z, Galvez-Peralta M, et al. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences – Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol 2013;84:304-13
   PubMed Web of Science ®Google Scholar
• Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. Annu Rev Pharmacol Toxicol 2012;52:37-56
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Gonzalez FJ. LC-MS-based metabolomics: an update. Arch Toxicol 2014;88:1491-502
   PubMed Web of Science ®Google Scholar
• Chen C, Ma X, Malfatti MA, et al. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol 2007;20:531-42
   PubMed Web of Science ®Google Scholar
• Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010;243:154-66
   PubMed Web of Science ®Google Scholar
• Geenen S, Taylor PN, Snoep JL, et al. Systems biology tools for toxicology. Arch Toxicol 2012;86:1251-71
   PubMed Web of Science ®Google Scholar
• Bouhifd M, Hartung T, Hogberg HT, et al. Review: toxicometabolomics. J Appl Toxicol 2013;33:1365-83
   PubMed Web of Science ®Google Scholar
• Lindon JC, Keun HC, Ebbels TM, et al. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 2005;6:691-9
   PubMed Web of Science ®Google Scholar
• Boudonck KJ, Rose DJ, Karoly ED, et al. Metabolomics for early detection of drug-induced kidney injury: review of the current status. Bioanalysis 2009;1:1645-63
   PubMed Web of Science ®Google Scholar
• Kamp H, Fabian E, Groeters S, et al. Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Bioanalysis 2012;4:2291-301
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002;1:153-61
   PubMed Web of Science ®Google Scholar
• Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008;21:9-27
   PubMed Web of Science ®Google Scholar
• Song BJ, Veech RL, Park SS, et al. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989;264:3568-72
   PubMed Web of Science ®Google Scholar
• Koop DR, Casazza JP. Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J Biol Chem 1985;260:13607-12
   PubMed Web of Science ®Google Scholar
• Chen C, Krausz KW, Idle JR, Gonzalez FJ. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 2008;283:4543-59
   PubMed Web of Science ®Google Scholar
• Chen C, Gonzalez FJ, Idle JR. LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 2007;39:581-97
   PubMed Web of Science ®Google Scholar
• Chen C, Krausz KW, Shah YM, et al. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2009;22:699-707
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Animal models for human risk assessment: the peroxisome proliferator-activated receptor alpha-humanized mouse. Nutr Rev 2007;65:S2-6
   PubMed Web of Science ®Google Scholar
• Jogl G, Hsiao YS, Tong L. Structure and function of carnitine acyltransferases. Ann N Y Acad Sci 2004;1033:17-29
   PubMed Web of Science ®Google Scholar
• Patterson AD, Shah YM, Matsubara T, et al. Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology 2012;56:281-90
   PubMed Web of Science ®Google Scholar
• Donadelli M, Dando I, Fiorini C, Palmieri M. UCP2, a mitochondrial protein regulated at multiple levels. Cell Mol Life Sci 2014;71:1171-90
   PubMed Web of Science ®Google Scholar
• Neuman MG, French SW, French BA, et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol 2014;97:492-510
   PubMed Web of Science ®Google Scholar
• Nakajima T, Kamijo Y, Tanaka N, et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004;40:972-80
   PubMed Web of Science ®Google Scholar
• Manna SK, Patterson AD, Yang Q, et al. Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. J Proteome Res 2010;9:4176-88
   PubMed Web of Science ®Google Scholar
• Manna SK, Patterson AD, Yang Q, et al. UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model. J Proteome Res 2011;10:4120-33
   PubMed Web of Science ®Google Scholar
• Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 2014;14:801-14
   PubMed Web of Science ®Google Scholar
• Matsubara T, Tanaka N, Krausz KW, et al. Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. Cell Metab 2012;16:634-44
   PubMed Web of Science ®Google Scholar
• Stehr M, Elamin AA, Singh M. Filling the pipeline - new drugs for an old disease. Curr Top Med Chem 2014;14:110-29
   PubMed Web of Science ®Google Scholar
• Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009;106:14728-33
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Cheng J, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013;19:418-20
   PubMed Web of Science ®Google Scholar
• Hofmann AF. Bile acids: trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009;49:1403-18
   PubMed Web of Science ®Google Scholar
• Chiang JY. Bile acid metabolism and signaling. Compr Physiol 2013;3:1191-212
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. Nuclear receptor control of enterohepatic circulation. Compr Physiol 2012;2:2811-28
   PubMed Web of Science ®Google Scholar
• Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol 2013;368:17-29
   PubMed Web of Science ®Google Scholar
• Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. Aids 2009;23:279-91
   PubMed Web of Science ®Google Scholar
• Cheng J, Fang ZZ, Kim JH, et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J Lipid Res 2014;55:455-65
   PubMed Web of Science ®Google Scholar
• Deo AK, Bandiera SM. 3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acid. Drug Metab Dispos 2009;37:1938-47
   PubMed Web of Science ®Google Scholar
• Matsubara T, Yoshinari K, Aoyama K, et al. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Dispos 2008;36:2058-63
   PubMed Web of Science ®Google Scholar
• Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. Aids 1997;11:F29-33
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003;23:183-94
   PubMed Web of Science ®Google Scholar
• Bruno R, Sacchi P, Maiocchi L, et al. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis 2006;38:363-73
   PubMedGoogle Scholar
• Guengerich FP, MacDonald JS. Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 2007;20:344-69
   PubMed Web of Science ®Google Scholar
• Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31
   PubMed Web of Science ®Google Scholar
• Denissen JF, Grabowski BA, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 1997;25:489-501
   PubMed Web of Science ®Google Scholar
• Li F, Lu J, Ma X. Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol 2011;24:2109-14
   PubMed Web of Science ®Google Scholar
• Struble KA, Pratt RD, Gitterman SR. Toxicity of antiretroviral agents. Am J Med 1997;102:65-7. discussion 68-9
   PubMedGoogle Scholar
• Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004;44:1273-81
   PubMed Web of Science ®Google Scholar
• Haas DW, Koletar SL, Laughlin L, et al. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 2009;50:290-3
   PubMed Web of Science ®Google Scholar
• Jamois C, Riek M, Schmitt C. Potential hepatotoxicity of efavirenz and saquinavir/ritonavir coadministration in healthy volunteers. Arch Drug Inf 2009;2:1-7
   PubMedGoogle Scholar
• Nijland HM, L’Homme R F, Rongen GA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008;22:931-5
   PubMed Web of Science ®Google Scholar
• Shi X, Yao D, Chen C. Identification of N-acetyltaurine as a novel metabolite of ethanol through metabolomics-guided biochemical analysis. J Biol Chem 2012;287:6336-49
   PubMed Web of Science ®Google Scholar
• Li F, Pang X, Krausz KW, et al. Stable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology. J Proteome Res 2013;12:1369-76
   PubMed Web of Science ®Google Scholar
• Fernandez-Salguero P, Pineau T, Hilbert DM, et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995;268:722-6
   PubMed Web of Science ®Google Scholar
• Schmidt JV, Su GH, Reddy JK, et al. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 1996;93:6731-6
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001;98:3369-74
   PubMed Web of Science ®Google Scholar
• Xie W, Barwick JL, Downes M, et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000;406:435-9
   PubMed Web of Science ®Google Scholar
• Wei P, Zhang J, Egan-Hafley M, et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000;407:920-3
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Smith AG, Ure J, et al. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 1998;95:5275-80
   PubMed Web of Science ®Google Scholar
• Henderson CJ, Wolf CR. Knockout and transgenic mice in glutathione transferase research. Drug Metab Rev 2011;43:152-64
   PubMed Web of Science ®Google Scholar
• Nguyen N, Bonzo JA, Chen S, et al. Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem 2008;283:7901-11
   PubMed Web of Science ®Google Scholar
• Scheer N, Ross J, Rode A, et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 2008;118:3228-39
   PubMed Web of Science ®Google Scholar
• Luisier R, Lempiainen H, Scherbichler N, et al. Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptors. Toxicol Sci 2014;139:501-11
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-12
   PubMed Web of Science ®Google Scholar
• Kakuni M, Morita M, Matsuo K, et al. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett 2012;214:9-18
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K. Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver. Xenobiotica 2014;44:123-34
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8
   PubMed Web of Science ®Google Scholar
• Takai S, Higuchi S, Yano A, et al. Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. J Appl Toxicol 2015;35:142-51
   PubMed Web of Science ®Google Scholar
• Asgari S, Moslem M, Bagheri-Lankarani K, et al. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev 2013;9:493-504
   PubMed Web of Science ®Google Scholar